News | October 06, 2024
Dr. Reddy’s Laboratories Switzerland incorporates a subsidiary in Denmark
he company will focus on production of any pharmaceutical and biotechnological products
he company will focus on production of any pharmaceutical and biotechnological products
He holds a Master’s in Management from the National University of Singapore
This office will be the central hub for all operations related to companies ethical pharmaceutical business
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Subscribe To Our Newsletter & Stay Updated
